{"id":4479,"date":"2024-06-14T09:21:19","date_gmt":"2024-06-14T01:21:19","guid":{"rendered":"https:\/\/superdna.nazsoftech.com\/?post_type=article&p=4479"},"modified":"2025-06-20T12:38:46","modified_gmt":"2025-06-20T04:38:46","slug":"pharmacogenomics-drug-response-malaysia","status":"publish","type":"article","link":"https:\/\/mysuperdna.com\/zh\/article\/pharmacogenomics-drug-response-malaysia\/","title":{"rendered":"How Pharmacogenetic Testing is Revolutionising Adverse Drug Reaction Prevention"},"content":{"rendered":"

If you’ve ever experienced unpleasant side effects from medication, you’re not alone. Adverse drug reactions (ADRs)<\/strong> affect up to 40% of patients<\/strong>, contributing to 15% of hospital spending in OECD countries. What many don\u2019t realize is that genetic differences<\/strong> are often behind these reactions.<\/p>\n

This is where pharmacogenomics – <\/strong>the study of how genes affect drug response\u2014comes into play.<\/p>\n

\n

\ud83e\uddec How Genetics Affects Medication Response<\/h3>\n

Your body\u2019s ability to absorb, metabolize, and eliminate drugs<\/strong> depends on a group of genes that code for drug-metabolizing enzymes. A single genetic variation<\/strong> can determine whether a drug is safe, effective, or potentially toxic<\/strong> for you.<\/p>\n

For example:<\/p>\n

\ud83d\udd39 DPYD Gene & Chemotherapy Toxicity<\/h4>\n

Patients with variations in the DPYD gene<\/strong> are at higher risk for severe side effects<\/strong> from fluoropyrimidine-based chemotherapy (used in colorectal, breast, and gastric cancers).
These reactions may include:<\/p>\n